Evidence map›Paper›PMID 38903549›Full record

ArticleJournal of advanced pharmaceutical technology & research

A novel dihydroacridine derivative targets epidermal growth factor receptor-expressing cancer cells

Anna Epishkina, Viktoria Pakina, Ekaterina Kutorkina, Evgeniia Bogoslovskaya, Oksana Tumutolova, Matvey Tolstov, Aleksandra Igrunkova, Ilya Fedoseikin, Ekaterina Blinova, Elena Semeleva and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of advanced pharmaceutical technology & research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anna EpishkinaDepartment of Clinical Pharmacology and Internal Diseases Propaedeutic, Sechenov University Mephi, Russia.
Viktoria PakinaDepartment of Clinical Pharmacology and Internal Diseases Propaedeutic, Sechenov University Mephi, Russia.
Ekaterina KutorkinaDepartment of Clinical Pharmacology and Internal Diseases Propaedeutic, Sechenov University Mephi, Russia.
Evgeniia BogoslovskayaDepartment of Clinical Pharmacology and Internal Diseases Propaedeutic, Sechenov University Mephi, Russia.
Oksana TumutolovaDepartment of Pharmacology and Pharmaceutics, Ogarev National Research Mordovia State University, Saransk, Russia.
Matvey TolstovDepartment of Clinical Pharmacology and Internal Diseases Propaedeutic, Sechenov University Mephi, Russia.
Aleksandra IgrunkovaDepartment of Clinical Pharmacology and Internal Diseases Propaedeutic, Sechenov University Mephi, Russia.
Ilya FedoseikinDepartment of Clinical Pharmacology and Internal Diseases Propaedeutic, Sechenov University Mephi, Russia.
Ekaterina BlinovaDepartment of Clinical Pharmacology and Internal Diseases Propaedeutic, Sechenov University Mephi, Russia.
Elena SemelevaDepartment of Pharmacology and Pharmaceutics, Ogarev National Research Mordovia State University, Saransk, Russia.
Dmitrii BlinovDepartment of Molecular and Clinical Pharmacology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small molecules are considered a source of novel medicines targeting carcinogenic intracellular pathways including epidermal growth factor receptor (EGFR) signaling. The main goal of the study is to assess whether LHT-17-19 could be considered an effective target molecule against EGFR-expressing tumor cells

Indexed as

Breast cancercell culturedihydroacridine derivativeepidermal growth factor receptormolecular dockingpatient-derived organoid

Identifiers

PMID38903549
PMCPMC11186549

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.